Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs
Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

Trevogrumab plus semaglutide

INVESTIGATIONAL

Myostatin inhibition combined with GLP-1 receptor agonism

1
graded results
0
ongoing records
1
effect domains
Evidence spread
High evidence 0Moderate evidence 0Low evidence 1Very low evidence 0

Trevogrumab plus semaglutide is investigational in the scoped programme below. Study records do not establish approval, safety or personal suitability. Results describe observations and do not provide treatment advice.

Dated status sources

INVESTIGATIONAL Global programme; Lean-mass preservation during semaglutide-associated weight loss; Co-administered intravenous trevogrumab and subcutaneous semaglutide; as of 2026-07-13. ClinicalTrials.gov

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Trevogrumab plus semaglutide INVESTIGATIONAL
body-composition Mixed
Low evidence

COURAGE phase-2 (Regeneron, NCT06299098) tests trevogrumab (anti-myostatin) +/- garetosmab (anti-activin A) added to semaglutide. Interim results show dose-ordered...

Regeneron press / EASD 2025 presentation Source
Full findingCOURAGE phase-2 (Regeneron, NCT06299098) tests trevogrumab (anti-myostatin) +/- garetosmab (anti-activin A) added to semaglutide. Interim results show dose-ordered lean preservation, with the triplet most lean-preserving but least tolerated. Final readout pending.
PopulationCOURAGE phase-2, N=1,005 actual, 26-week interim (EASD 2025); semaglutide 2.4 mg +/- trevogrumab +/- garetosmab; adults with obesity without diabetes; completion ~late 2026.
Fundingindustry - Novo Nordisk (trial sponsor; inferred from registration trial)
Comparatorssemaglutide 2.4 mg alone; placebo